



## Sana Biotechnology to Host Research & Development Day

April 24, 2023

SEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that management will host a Research & Development (R&D) Day on Tuesday, May 23, 2023 from 9:00 a.m. – 12:00 p.m. ET in New York, NY.

The event will include a comprehensive overview of Sana's R&D portfolio, with a focus on programs within the hypimmune and fusogen platforms, including additional information on the two programs with clinical proof of concept trials expected this year – SC291, the hypimmune-modified CD19-targeted allogeneic CAR T product candidate for B-cell malignancies and the investigator-sponsored trial using hypimmune-modified primary human islet cells for type 1 diabetes.

A live webcast and archived replay of the event will be accessible on the Investor Relations page of Sana's website at <https://sana.com/>.

### About Sana Biotechnology

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information about Sana Biotechnology, please visit <https://sana.com/>.

### Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws, including those related to the Company's vision, progress, and business plans and expectations for its development programs, product candidates and technology platforms, including with respect to clinical trials and expected timing and impact thereof; and expectations for hosting a potential R&D Day event, including the timing of and subject matter of the presentations at such event. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company's strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company's current and future research and development programs, preclinical and clinical trials, as well as economic, market, and other disruptions, including due to the COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's SEC reports, including but not limited to its Annual Report on Form 10-K dated March 16, 2023. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

### Investor Relations & Media:

Nicole Keith

[investor.relations@sana.com](mailto:investor.relations@sana.com)

[media@sana.com](mailto:media@sana.com)